Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals (Nasdaq: ADMS) has granted restricted stock units (RSUs) to three new employees, totaling 38,500 shares. These RSUs will vest over three years and are part of the Adamas Pharmaceuticals 2016 Inducement Plan, approved by the board in March 2016. The plan is designed to attract new talent to advance the company's mission of delivering innovative neurological therapies. For further details, visit www.adamaspharma.com.
- The issuance of RSUs may enhance employee retention and motivation.
- The plan aligns with the company's strategy to attract talent for its portfolio development.
- None.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210813005399/en/
FAQ
What is the recent stock grant news from Adamas Pharmaceuticals?
How many shares were granted by Adamas Pharmaceuticals?
What is the purpose of the 2016 Inducement Plan by Adamas Pharmaceuticals?